ArticleInternational ophthalmology2025
Nesfatin-1 alleviates blue-light-emitting diodes induced retinal damage in Sprague-Dawley rats.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLight-emitting diodes (LEDs) are extensively used across various devices and applications. However, the effects of prolonged or excessive exposure to white and blue LED light on the retina remain inadequately understood.
methodsThis study investigated the impact of such exposure over 14 weeks on retinal structural and morphological changes and the potential protective effect of nesfatin-1 (N1) administered subcutaneously (0.5 mg/kg body weight) during the final two weeks. Three-week-old Sprague Dawley rats (n = 40) were assigned to six groups: two control groups (C = standard fluorescent lighting; CS = C + sesame oil) and four experimental groups (blue LED, white LED, blue LED + N1, and white LED + N1). Blood and eye samples were collected for biochemical and histopathological analysis at the end of the study.
resultsThe blue LED exposure group exhibited significantly elevated serum nesfatin-1 levels (p < 0.001) and reduced concentrations of melatonin and adrenocorticotropic hormone (ACTH; p < 0.05). The retina displayed normal, well-defined structural and morphological features in both control groups, including distinct boundaries and orderly nuclear layer cells between the inner and outer segments. However, slight disorganization of the nuclear layers and a few irregular nuclei were observed in the CS group. Cell loss and damage were more prominent in the LED-exposed groups in both the inner and outer retinal segments and nuclear layers, accompanied by other notable histopathological changes. The inner and outer retinal structures in both white LED groups showed mild disorganization, characterized by irregular nuclei and a noticeable reduction in nuclear layer cells. Retinal damage in both blue LED groups was more pronounced, with marked rod cell loss, disrupted arrangement of the inner and outer plexiform and nuclear layers, and irregular nuclei. Prolonged exposure to blue LED light induced edema in the photoreceptor layers; however, nesfatin-1 administration significantly reduced this inflammation and mitigated other pathological alterations.
conclusionBiochemical and histological findings indicated that blue LED exposure may disrupt physiological systems by lowering melatonin and ACTH levels, potentially triggering compensatory nesfatin-1 secretion through a rapid feedback mechanism. These results underscore the need for further investigation into the effects of long-term exposure to short-wavelength light on retinal integrity and highlight the possible utility of nesfatin-1 as a biomarker in stress response regulation.
Indexed as
Identifiers
40848073What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.